BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that data presented at the 14th Congress of the European Society of Hematology demonstrate that treatment with VIDAZA significantly extends overall survival and helps patients with myelodysplastic syndromes (MDS) become or remain red blood cell transfusion independent. Patients who benefited included those with higher-risk MDS or acute myeloid leukaemia (AML) with 20-30% blasts, as defined by the World Health Organization (WHO).
